The global auto-injectors market is predicted to rise at a healthy CAGR during the forecast period. Demand for auto-injectors could show strong growth due to the increase in the incidence of food and skin allergies and anaphylaxis. Patients are observed to prefer using auto-injectors over conventional injection systems because of the advantages of controlled drug delivery, increased efficacy, consistent dose accuracy, decreased risk of needle stick injuries, and reduced needle phobia. Innovation could play a major role in the advancement of auto-injectors.
Late in September 2019, Aterica Digital Health, a Canadian consumer-focused digital health company, announced that its comprehensive anaphylaxis and food allergy support system Veta Smart Case & App is available in Walgreens stores. The Veta system is used for managing epinephrine auto-injectors such as EPIPEN.
Large Number of Patients Opting for Self-administration of Injections to Augment Demand
High patient preference for self-administration of injectable medications is likely to promise excellent sales opportunities for auto-injector manufacturers. Compared to traditional injection devices, auto-injectors could help with improved and more efficient drug delivery. Rise in the incidence of anaphylactic shock could be a leading factor driving the growth of the global auto-injectors market. Technological advancement in the medical devices field and increasing innovation of injection systems and devices are expected to make considerable contributions to the overall growth of the global auto-injectors market.
Get PDF template of this report: https://www.qyrconsulting.com/request-sample/8133
Leading Companies to Diversify Product Portfolio and Focus on Innovation to Increase Profits
The report covers prominent players of the global auto-injectors market, such as Mylan, Medeca Pharma AB, BD, Antares Pharma, Inc., Johnson & Johnson, Owen Mumford, Amgen Inc., Eli Lilly, Kaleo, Inc., Biogen Idec, Ypsomed Holding, Bayer, and Meridian (Pfizer). Companies are expected to focus on the diversification of their product portfolio, introduction of innovative products, and signing of strategic merger and acquisition agreements to achieve a position of strength in the global auto-injectors market. In May 2019, Ypsomed, a Swiss manufacturer of injection and infusion systems for self-medication, announced that Teva Pharmaceutical Industries launched its drug product Copaxone with the pre-filled auto-injector YpsoMate.
By Product Type
- Disposable Auto-injectors
- Reusable Auto-injectors
By Disease Indication
- Multiple Sclerosis
- Rheumatoid Arthritis
Among product type segments, disposable is forecast to secure a significant share of the global auto-injectors market because of its increased adoption. Favorable factors such as high patient preference, convenience, low infection risk, and ease of use are expected to drive the demand for disposable auto-injectors.
Market Analysis by Regions and Countries
The Middle East and Africa (GCC Countries and Egypt.)
North America (the United States, Mexico, and Canada.)
South America (Brazil etc.)
Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia.)
Purchase Complete Report within 24 hours: https://www.qyrconsulting.com/checkout/8133
QYR Consulting established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.